ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0077

Circulating CD4+CXCR5-PD-1hiICOS+ Cells Are Elevated in Patients with Newly Diagnosed Giant Cell Arteritis and Associate with the Clinical Outcome

Maria-Eugenia Miranda-Carus1, Beatriz Nieto-Carvalhal1, Irene Monjo2, Mariela Uyaguari-Morocho1, Irene Casado-Juárez3, Alejandro Balsa4 and Eugenio De Miguel4, 1Hospital Universitario La Paz - IdiPAZ, Madrid, Spain, 2University Hospital La Paz, Madrid, Spain, 3Hospital La Paz - IdiPAZ, Madrid, Spain, 4Hospital Universitario La Paz, Madrid, Spain

Meeting: ACR Convergence 2023

Keywords: giant cell arteritis, immunology, T Cell, T-Lymphocyte

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0066–0095) T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Giant cell arteritis (GCA) is a large-vessel granulomatous vasculitis. It is characterized by the presence at the inflamed arterial walls, of activated PD-1+ CD4 T cells; this contrasts with observations indicating that a defect of PD-1 signaling is implicated in the pathogenesis of GCA. A population of CD4+CXCR5-PD-1hi cells, termed Tph cells, has been described at the inflamed synovium and peripehral blood of patients with Rheumatoid Arthritis, and seem to play a pathogenic role in this condition. Our objective was to study the frequencies of circulating total Tph (cTph) and activated ICOS+Tph (cICOS+Tph) cells in the peripheral blood of patients with newly diagnosed GCA (nGCA) and examine whether they are related with the clinical outcome.

Methods: This is a prospective non-interventional study performed on consecutive patients referred to our ultrasound (US) GCA fast track clinic, in whom newly diagnosed GCA (nGCA) was clinically confirmed (2022 ACR/EULAR criteria) over a period of 18 months. Peripheral blood was drawn immediately upon confirmation and after obtaining written informed consent. For each patient, an age and gender-matched healthy control (HC) was also studied. PBMCs isolated by Ficoll- Hypaque gradient were stained with antibodies to CD3, CD4, CD45RA, CD45RO, CXCR5, ICOS, PD-1, and examined by flow cytometry. Patients were treated with standard therapy according to clinical response.

Results: A total of 48 nGCA patients were included (mean age 81,5 years, 50.0 % female). As compared with HC, nGCA patients presented at baseline with an increased frequency of cTph and cICOS+Tph cells. Among the 26 patients who could be followed up for 12 months (the remaining 22 have been diagnosed less than 12 months ago),8 experienced a relapse (2018 EULAR recommendations; symptoms plus: elevation of acute phase reactants and/or positive US). Interestingly, the basal frequency of cICOS+Tph cells had been significantly lower in patients who relapsed as compared with those who did not; the frequency of cTph cells also tended to be lower in relapsing subjects but the difference with non-relapsing patients was not statistically significant.

Conclusion: Newly diagnosed GCA patients demonstrate an increased frequency of cTph and cICOS+Tph cells. Lower basal proportions of cICOS+ Tph cells are associated with relapse.

Supporting image 1


Disclosures: M. Miranda-Carus: Bristol-Myers Squibb(BMS), 5, Gebro Pharma, 5; B. Nieto-Carvalhal: None; I. Monjo: Amgen, 6, Gedeon Richter, 6, Janssen, 6, Novartis, 6, Roche, 6, UCB, 6; M. Uyaguari-Morocho: None; I. Casado-Juárez: None; A. Balsa: AbbVie/Abbott, 1, 2, 5, 6, Bristol-Myers Squibb(BMS), 1, 5, Eli Lilly, 1, 5, 6, Merck/MSD, 1, 5, Novartis, 5, Pfizer, 1, 5, 6, UCB, 1, 5, 6; E. De Miguel: None.

To cite this abstract in AMA style:

Miranda-Carus M, Nieto-Carvalhal B, Monjo I, Uyaguari-Morocho M, Casado-Juárez I, Balsa A, De Miguel E. Circulating CD4+CXCR5-PD-1hiICOS+ Cells Are Elevated in Patients with Newly Diagnosed Giant Cell Arteritis and Associate with the Clinical Outcome [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/circulating-cd4cxcr5-pd-1hiicos-cells-are-elevated-in-patients-with-newly-diagnosed-giant-cell-arteritis-and-associate-with-the-clinical-outcome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/circulating-cd4cxcr5-pd-1hiicos-cells-are-elevated-in-patients-with-newly-diagnosed-giant-cell-arteritis-and-associate-with-the-clinical-outcome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology